CN118742316A - 用于抑制癌转移的vipr2拮抗肽 - Google Patents
用于抑制癌转移的vipr2拮抗肽 Download PDFInfo
- Publication number
- CN118742316A CN118742316A CN202280092332.XA CN202280092332A CN118742316A CN 118742316 A CN118742316 A CN 118742316A CN 202280092332 A CN202280092332 A CN 202280092332A CN 118742316 A CN118742316 A CN 118742316A
- Authority
- CN
- China
- Prior art keywords
- acid
- peptide
- cells
- group
- vipr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-027791 | 2022-02-25 | ||
| JP2022027791 | 2022-02-25 | ||
| PCT/JP2022/047969 WO2023162456A1 (ja) | 2022-02-25 | 2022-12-26 | 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118742316A true CN118742316A (zh) | 2024-10-01 |
Family
ID=87765588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280092332.XA Pending CN118742316A (zh) | 2022-02-25 | 2022-12-26 | 用于抑制癌转移的vipr2拮抗肽 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250186540A1 (https=) |
| EP (1) | EP4473973A4 (https=) |
| JP (1) | JP7339471B1 (https=) |
| CN (1) | CN118742316A (https=) |
| WO (1) | WO2023162456A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4137502A4 (en) * | 2020-03-30 | 2024-02-28 | Ichimaru Pharcos Co., Ltd. | Vipr2 antagonist peptide |
-
2022
- 2022-12-26 CN CN202280092332.XA patent/CN118742316A/zh active Pending
- 2022-12-26 WO PCT/JP2022/047969 patent/WO2023162456A1/ja not_active Ceased
- 2022-12-26 EP EP22928971.5A patent/EP4473973A4/en active Pending
- 2022-12-26 US US18/841,363 patent/US20250186540A1/en active Pending
- 2022-12-26 JP JP2023528145A patent/JP7339471B1/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4473973A4 (en) | 2026-01-21 |
| WO2023162456A1 (ja) | 2023-08-31 |
| EP4473973A1 (en) | 2024-12-11 |
| JPWO2023162456A1 (https=) | 2023-08-31 |
| US20250186540A1 (en) | 2025-06-12 |
| JP7339471B1 (ja) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6426103B2 (ja) | ｃ−Ｍｅｔタンパク質アゴニスト | |
| US9937240B2 (en) | Peptide having fibrosis inhibitory activity and composition containing same | |
| JP5355561B2 (ja) | 生物活性ペプチドおよびその使用方法 | |
| TW202535916A (zh) | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 | |
| KR20010023449A (ko) | 신규한 환상 테트라펩티드 유도체 및 그 의약 용도 | |
| KR20090090315A (ko) | 메타스틴 유도체 및 그의 용도 | |
| KR101368607B1 (ko) | 메타스틴 유도체 및 그의 용도 | |
| JP4335910B2 (ja) | メタスチン誘導体およびその使用 | |
| JP2025036429A (ja) | プロテアーゼ活性化受容体２のモジュレーター | |
| JP2009523157A (ja) | 虚血および神経変性の処置のための化合物 | |
| US20220227813A1 (en) | Ras INHIBITORY PEPTIDE | |
| ES2400567T3 (es) | Inhibidores de cinasa de la cadena ligera de miosina y su uso | |
| JP6735676B2 (ja) | Ｃ−ｆｏｓの選択的インヒビターおよびその抗増殖特性 | |
| CN118742316A (zh) | 用于抑制癌转移的vipr2拮抗肽 | |
| JP7417010B1 (ja) | 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド | |
| WO2021200259A1 (ja) | Ｖｉｐｒ２アンタゴニストペプチド | |
| JP7181550B2 (ja) | ペプチド、その薬学的に許容される塩、またはそれらのプロドラッグ、およびそれらの用途 | |
| JP7464310B2 (ja) | Ｗｎｔシグナル伝達経路の抑制剤 | |
| JP2011512364A (ja) | 治療用ペプチド | |
| JPWO2014119753A1 (ja) | マイオスタチン阻害ペプチド | |
| US20210395310A1 (en) | Cyclic Peptide | |
| WO2005115394A2 (en) | Prenyl-electrostatic switch, and methods of use | |
| US11541101B1 (en) | LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol | |
| WO2019117691A1 (ko) | CD44v6에 결합하는 펩타이드 및 이의 용도 | |
| WO2016038608A1 (en) | Peptides derived from angiotensin receptor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |